Abstract

The social and financial burden of stroke is remarkable. Stroke is a leading cause of death and long-term disability worldwide. For several years, intravenous recombinant tissue plasminogen activator (IV rt-PA) remained as the only proven therapy for acute ischemic stroke. However, its benefit is hampered by a narrow therapeutic window and limited efficacy for large vessel occlusion (LVO) strokes. Recent trials of endovascular therapy (EVT) for LVO strokes have demonstrated improved patient outcomes when compared to treatment with medical treatment alone (with or without IV rt-PA). Thus, EVT has become a critical component of stroke care. As in IV rt-PA, time to treatment is a crucial factor with high impact on outcomes. Unlike IV rt-PA, EVT is only available at a limited number of centers. Considering the time sensitive benefit of reperfusion therapies of acute ischemic stroke, costs and logistics associated, it is recommended that regional systems of acute stroke care should be developed. These should include rapid identification of suspected stroke, centers that provide initial emergency care, including administration of IV rt-PA, and centers capable of performing endovascular stroke treatment with comprehensive periprocedural care to which rapid transport can be arranged when appropriate. In the pre-hospital setting, the development of scales easier and quicker to perform than the NIHSS yet with a maintained accuracy for detecting LVO strokes is of paramount importance. Several scales have been developed. On the other hand, the decision whether to transport to a primary stroke center (PSC) or to a comprehensive stroke center (CSC) is complex and far beyond the simple diagnosis of a LVO. Ongoing studies will provide important answers to the best transfer strategy for acute stroke patients. At the same time, the development of new technologies to aid in real time the decision-making process will simplify the logistics of regional systems for acute stroke care and, likely improve patients' outcomes through tailored selection of the most appropriate recanalization strategy and destination center.

Highlights

  • The social and financial burden of stroke is remarkable

  • Considering the time sensitive benefit of reperfusion therapies of acute ischemic stroke as well as the costs and complex logistics associated, it is highly recommended that regional systems of acute stroke care should be developed

  • A recent systematic review favors the MS model over the drip-and-ship model (DS) for patients with suspected large vessel occlusion (LVO). Those patients that were primarily direct to a comprehensive stroke center (CSC) (MS model) had significantly better outcomes than patients that were first directed to a primary stroke center (PSC) and transferred to a CSC (DS model) (90-day modified Rankin scale (mRS) 0–2: 60.0% vs. 52.2%; OR, 1.38; 95% CI [1.06–1.79]; p = 0.02)

Read more

Summary

INTRODUCTION

Stroke is the second leading cause of death and the first cause of longterm disability worldwide [1]. At the pre-hospital setting, the primary goal for emergency medical services (EMS) is to ensure that stroke patients receive the fastest and most appropriate triage in order to optimize their chances of receiving reperfusion treatment. The contrasting efficacy for different types of ischemic strokes and the imbalance of the availability of treatments lead to a complex decision where time to treatment has to be weighed against effectiveness in any given clinical scenario. We will discuss different aspects involved in the complex decision-making process for pre-hospital assessment and triage of stroke patients as well as current trends that will probably impact future directions in the field

THE EVOLVING FIELD OF REPERFUSION THERAPIES IN ACUTE ISCHEMIC STROKE
Findings
Parameters assessed
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call